Bruno Sangro, EASL ILC 2021: Early Phase Data on Checkpoint Inhibitors in HCC
It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!